Business Wire

SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children

27.11.2025 09:15:00 EET | Business Wire | Press release

Share

SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/

Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia".

This investigator-initiated trial is part of an ongoing project investigating the efficacy of omega-3 and omega-6 LCPUFA supplementation to enhance the effects of neuropsychological treatment in children diagnosed with developmental dyslexia (DD).

LCPUFAs of the omega-3 group, such as EPA and DHA, play essential roles in microglial activity, neuroinflammatory regulation, and synaptic plasticity—processes crucial for brain health and learning. Previous research has shown that individuals with dyslexia tend to have lower levels of these fatty acids in their blood, and this deficiency has been associated with slower and less accurate reading and writing performance.

The new study set out to determine which neurocognitive systems mediate the relationship between omega-3 LCPUFA levels and literacy skills in school-age children.

Seventy-four children with reading and writing skills ranging from normal to below average (DD) took part in an extensive neuropsychological assessment. Tasks evaluated reading and writing, auditory and visual processing (including measures related to magnocellular function), phonological awareness, attention, and executive functioning.

Researchers extracted three key neuropsychological factors—Auditory Phonological (AP), Visual-Perceptual (VP), and Visual-Attentional (VA) processing—and tested their mediating role between omega-3 LCPUFA levels and literacy performance using Generalized Linear Model mediation analyses. Interactions with other polyunsaturated fatty acids (PUFAs) were also examined.

The study found that omega-3 LCPUFA levels, especially EPA and DHA, were significantly correlated with children’s reading and writing abilities as well as with the three identified cognitive factors.

  • Auditory-phonological processing emerged as a significant mediator of the effects of PUFAs—particularly EPA—on literacy performance.
  • DHA and the AA/ALA ratio (the balance between arachidonic acid and alpha-linolenic acid) significantly affected the strength and direction of some of these relationships.

Dr. Maria Luisa Lorusso, Child Neuropsychologist and senior Researcher in the Department of Child Psychopathology at Scientific Institute IRCSS E. Medea, and responsible for the study, commented: “We are very excited to share these findings which provide new insight into how omega-3 fatty acids influence reading and writing development through their action on specific neurocognitive processes, particularly auditory-phonological mechanisms. We are grateful to SFI Health™ for their support along this study which underlines also the importance of the balance between different PUFAs in determining the overall cognitive benefits.”

Matthew Brabazon, General Manager at SFI Health™ EMEA, added: ”As a company that views research as a fundamental pillar of its mission to offer science-based natural healthcare products, we are extremely proud of this achievement. SFI Health™ has a long-standing tradition of strategic partnerships with leading universities and researchers around the world, all with the shared goal of combining expertise and capabilities to unlock the potential of natural-source ingredients for human health.”

While more research is needed to confirm whether increasing omega-3 intake can directly improve reading and writing skills, this study provides a valuable foundation for future work on the connections between diet, brain function, and learning.

Link to the publication: https://www.mdpi.com/2227-9059/13/10/2517#.

About SFI Health

SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.

Guided by the belief in the healing potential of natural products, SFI Health™combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.

An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.

SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.

For more information go to sfihealth.com or follow us SFI Health on LinkedIn.

About IRCCS Medea of La Nostra Famiglia

Since 1985, the Scientific Institute IRCCS Eugenio Medea – La Nostra Famiglia has been committed to research, care, and rehabilitation in the field of neurological and neuropsychiatric disorders affecting children and adolescents. It operates in Bosisio Parini (Lecco), Conegliano (Treviso), and Pasian di Prato (Udine).

The Institute’s mission is to build strong connections between scientific research, clinical care, and technological innovation—always “on the side of children”—to safeguard their dignity and enhance the quality of life of its young patients.

For more info, please visit emedea.it or follow us on facebook - emedea.lanostrafamiglia, instagram - emedea_lanostrafamiglia, linkedin - associazione-la-nostra-famiglia

View source version on businesswire.com: https://www.businesswire.com/news/home/20251126097656/en/

Contacts

For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com

IRCCS Medea of La Nostra Famiglia Contact
e-mail address: ufficio.stampa@lanostrafamiglia.it

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye